A Three-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of AC-084 in Healthy Subjects and to Investigate the Pharmacokinetics of a Single Dose of AC-084 in Healthy CYP2C9 Poor Metabolizers

Trial Profile

A Three-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of AC-084 in Healthy Subjects and to Investigate the Pharmacokinetics of a Single Dose of AC-084 in Healthy CYP2C9 Poor Metabolizers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs AC 084 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2017 Planned End Date changed from 31 Dec 2017 to 20 Dec 2017.
    • 06 Jul 2017 Planned primary completion date changed from 31 Dec 2017 to 20 Dec 2017.
    • 14 Jun 2017 Planned End Date changed from 31 May 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top